A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki disease is the leading cause of acquired heart disease in children in...
New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI), a serious complication affecting 35,000...
Company's C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial marketsJUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic...
LITTLETON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be...
Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX could play a central role in inflammatory signaling across high-impact...
SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO" or the "Company"), a healthcare services fertility company, today announced that on May 27, 2026, it received a delinquency notice (the "Notice") from the Listing...
SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and...
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients,...
IRIDEX Corporation (NASDAQ: IRIX) is a global ophthalmic medical technology company specializing in innovative laser-based systems for the treatment of glaucoma and retinal diseases. The company's portfolio includes laser platforms, delivery devices, and treatment...
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) is a biopharmaceutical company focused on developing therapies for patients with cardiovascular diseases and unmet medical needs. The company is advancing programs intended to address critical treatment gaps while improving...
Biofrontera Inc. (NASDAQ: BFRI) is a biopharmaceutical company focused on the commercialization of dermatological therapies and treatments for skin conditions. The company's portfolio includes products designed to address actinic keratosis and other dermatologic...
Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) is a clinical-stage biotechnology company focused on the development of targeted immunotherapies for the treatment of cancer and immune-mediated diseases. The company's proprietary Superkine platform is designed to...
Dyadic Applied BioSolutions (NASDAQ: DYAI) is focused on leveraging advanced microbial and protein expression technologies to support the development and manufacture of biopharmaceuticals, vaccines, and other biologic products. The company's proprietary technology...
PolyPid Ltd. (NASDAQ: PYPD) is a late-stage biopharmaceutical company developing innovative therapies designed to improve surgical outcomes and reduce post-operative complications. The company's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology enables...
Jaguar Health (Nasdaq: JAGX) is a commercial-stage pharmaceutical company focused on developing and commercializing plant-based prescription medicines for gastrointestinal conditions and supportive care. The company's portfolio includes therapies designed to address...
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a late-stage biopharmaceutical company focused on discovering, developing, and seeking to commercialize innovative therapies for diseases with significant unmet medical needs. The company's development programs...
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) is a medical technology company focused on developing innovative spinal implant technologies and minimally invasive surgical solutions. The company offers a portfolio of proprietary spinal fixation systems,...
Aytu BioPharma (NASDAQ: AYTU) is a pharmaceutical company focused on developing and commercializing prescription therapeutics that address unmet patient needs. The company's portfolio includes products across multiple therapeutic areas and is supported by...
Precision Optics Corporation, Inc. (NASDAQ: POCI) is a medical technology and advanced optics company specializing in the design, development, and manufacture of sophisticated imaging systems and optical components. The company serves healthcare and industrial markets...
Alpha Tau Medical (NASDAQ: DRTS) is an oncology-focused medical technology company developing alpha-radiation therapies designed to target and destroy solid tumors while minimizing damage to surrounding healthy tissue. The company's proprietary Alpha DaRT technology...
NeurAxis, Inc. (NYSE American: NRXS) is a medical technology company focused on neuromodulation therapies for chronic and debilitating conditions affecting children and adults. The company's proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS)...
Collaboration Leverages Prior Andes, Marburg and Ebola Virus Research and Dyadic's C1 Platform Capabilities for Fast, Scalable Biologic ProductionJUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company")...
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast...
JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company...
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Chief Executive Officer, and Jack Glenn, Chief Financial Officer, will...
PONTE VEDRA, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, will participate in a webcast presentation and host...
JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "our," or the "Company") (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and...
LITTLETON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, will participate in a webcast...
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will...
PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudited financial...
Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three...
Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industryCommercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic...
Conference Call Scheduled for today, May 13, 2026, at 5:00pm ETLITTLETON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and...
EXXUA -- with only a partial quarter of full sales force support -- contributed $2.4 million in net revenue supported by rapid monthly compounding script growth ratesTotal net revenue of $12.4 millionAdjusted EBITDA1 of $(2.8) million, which includes EXXUA™...
The second annual #HatsonforAK Campaign runs May 18-24, 2026, culminating on Global Actinic Keratosis (AK) Awareness DayThis social media-driven initiative invites people to wear a hat, share a photo, and help raise awareness of AK and the importance of comprehensive...
Conference call will be held today, Tuesday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and...
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial...
Conference Call Scheduled for Friday, May 15, 2026 at 9:00 AM ETPORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf...
Official FDA meeting minutes and Phase 2 data provide guidance on the pivotal Phase 3 registration path for CAD-1005 in heparin-induced thrombocytopenia (HIT)PONTE VEDRA, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage...
LITTLETON, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has...
DENVER, CO / ACCESS Newswire / May 6, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will...
Order supports customer's full launch, with shipments expected to commence shortly and be fulfilled over 12 -15 monthsLITTLETON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced...
CARMEL, Ind., May 05, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will...
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5 million, or 13%, compared to the same period in 2025.Reports record...
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE...
JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision...
SARASOTA, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation...
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on Friday, May 1, 2026. Iradimed management will host a conference call...
CARMEL, Ind., April 22, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced...
In this episode, we are featuring Kiora Pharmaceuticals (Nasdaq: KPRX), a clinical-stage biotechnology company developing advanced therapies for retinal disease. This interview is moderated by Robert Blum, Managing Partner at Lytham Partners, and features Brian Strem,...